Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

2016 Genitourinary Cancers Symposium

Entinostat and high-dose Interleukin 2 in renal cell carcinoma patients

Prof Roberto Pili - Indiana University, Indianapolis, USA

Entinostat and high-dose Interleukin 2 in renal cell carcinoma patients ( Prof Roberto Pili - Indiana University, Indianapolis, USA )

Gemcitabine plus cisplatin plus ipilimumab for metastatic urothelial cancer

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

Gemcitabine plus cisplatin plus ipilimumab for metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

Avelumab for metastatic urothelial carcinoma: JAVELIN trial

Dr Andrea Apolo - National Cancer Institute, Maryland, USA

Avelumab for metastatic urothelial carcinoma: JAVELIN trial ( Dr Andrea Apolo - National Cancer Institute, Maryland, USA )

Subgroup analyses of METEOR; randomized phase III trial of cabozantinib vs everolimus for RCC

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France

Subgroup analyses of METEOR; randomized phase III trial of cabozantinib vs everolimus for RCC ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )

Integrated genomic correlates of response to PD-1 inhibitor nivolumab in mRCC

Dr Guillermo de Velasco - Dana-Farber Cancer Institute, Boston, USA

Integrated genomic correlates of response to PD-1 inhibitor nivolumab in mRCC ( Dr Guillermo de Velasco - Dana-Farber Cancer Institute, Boston, USA )

Discontinuing VEGF-targeted therapy for progression or toxicity affects outcomes of second-line therapies in mRCC

Dr Guillermo de Velasco - Dana-Farber Cancer Institute, Boston, USA

Discontinuing VEGF-targeted therapy for progression or toxicity affects outcomes of second-line therapies in mRCC ( Dr Guillermo de Velasco - Dana-Farber Cancer Institute, Boston, USA )

Impact of metformin on outcomes for metastatic renal cell carcinoma

Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA

Impact of metformin on outcomes for metastatic renal cell carcinoma ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )

Comparing adjuvant radiotherapy plus chemo vs. adjuvant chemo following cystectomy for bladder cancer

Dr Brian Baumann - University of Pennsylvania, Philadelphia, USA

Comparing adjuvant radiotherapy plus chemo vs. adjuvant chemo following cystectomy for bladder cancer ( Dr Brian Baumann - University of Pennsylvania, Philadelphia, USA )

Molecular genetics of testicular cancer: What does the clinician need to know?

Dr Katherine Nathanson - University of Pennsylvania, Philadelphia, USA

Molecular genetics of testicular cancer: What does the clinician need to know? ( Dr Katherine Nathanson - University of Pennsylvania, Philadelphia, USA )

ASCO GU 2016: Highlights

Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA

ASCO GU 2016: Highlights ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )

Atezolizumab for platinum-treated locally advanced or metastatic urothelial carcinoma

Dr Jean Hoffman-Censits - Kimmel Cancer Center, Philadelphia, USA

Atezolizumab for platinum-treated locally advanced or metastatic urothelial carcinoma ( Dr Jean Hoffman-Censits - Kimmel Cancer Center, Philadelphia, USA )

Healthcare and QoL burden of symptomatic skeletal events in CRPC with bone mets

Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA

Healthcare and QoL burden of symptomatic skeletal events in CRPC with bone mets ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )

Regular aspirin use may reduce risk of dying from prostate cancer

Dr Christophe Allard - Massachusetts General Hospital, Boston, USA

Regular aspirin use may reduce risk of dying from prostate cancer ( Dr Christophe Allard - Massachusetts General Hospital, Boston, USA )

ASCO GU: Advances in prostate cancer from day one

Dr Axel Merseburger, Dr Eleni Efstathiou, Prof Karim Fizazi, Prof Nick James

ASCO GU: Advances in prostate cancer from day one ( Dr Axel Merseburger, Dr Eleni Efstathiou, Prof Karim Fizazi, Prof Nick James )

Alisertib for pretreated urothelial cancer

Dr Andrea Necchi - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Alisertib for pretreated urothelial cancer ( Dr Andrea Necchi - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy )

Link between non-aspirin NSAID use and risk of developing renal cell cancer

Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA

Link between non-aspirin NSAID use and risk of developing renal cell cancer ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )

Brentuximab vedotin as salvage therapy for men with relapsed germ-cell tumours

Dr Andrea Necchi - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Brentuximab vedotin as salvage therapy for men with relapsed germ-cell tumours ( Dr Andrea Necchi - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy )

Actionable targets in patients with cisplatin-resistant advanced germ cell tumours

Dr Aditya Bagrodia - Memorial Sloan Kettering New York, USA

Actionable targets in patients with cisplatin-resistant advanced germ cell tumours ( Dr Aditya Bagrodia - Memorial Sloan Kettering New York, USA )

More from ecancer